AB
AMLX icon

Amalgamated Bank’s Amylyx Pharmaceuticals AMLX Stock Holding History

Amalgamated Bank’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,788
Closed -$34K – 1675
2025
Q4 		$34K Buy
2,788
+419
+18% +$5.69K ﹤0.01% 1932
2025
Q3 		$32K Hold
2,369
– – ﹤0.01% 1964
2025
Q2 		$15K Buy
+2,369
New +$11.5K ﹤0.01% 2218
2024
Q2 		– Sell
-1,726
Closed -$5K – 3008
2024
Q1 		$5K Sell
1,726
-5,478
-76% -$71.6K ﹤0.01% 2688
2023
Q4 		$106K Sell
7,204
-513
-7% -$7.86K ﹤0.01% 1978
2023
Q3 		$141K Hold
7,717
– – ﹤0.01% 1896
2023
Q2 		$166K Buy
7,717
+2,054
+36% +$55.5K ﹤0.01% 1886
2023
Q1 		$166K Sell
5,663
-1,362
-19% -$47.3K ﹤0.01% 1871
2022
Q4 		$260K Buy
7,025
+2,247
+47% +$79.7K ﹤0.01% 1757
2022
Q3 		$135K Buy
4,778
+3,254
+214% +$81.2K ﹤0.01% 2007
2022
Q2 		$29K Sell
1,524
-239
-14% -$2.84K ﹤0.01% 2728
2022
Q1 		$23K Buy
+1,763
New +$39.8K ﹤0.01% 2752

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Amalgamated Bank's AMLX Position: Q1 2026 in Review

Amalgamated Bank sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2026, closing a stake of 2,788 shares — an estimated $34K sold.

Amalgamated Bank first reported a position in AMLX in Q1 2022 and held it in 12 quarters. The position peaked at $260K in Q4 2022. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Amalgamated Bank reported no remaining Amylyx Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 2,788 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $34K.
  • Amalgamated Bank first reported a position in Amylyx Pharmaceuticals in Q1 2022 and held it in 12 quarters.
  • Amalgamated Bank's Amylyx Pharmaceuticals position peaked at $260K in Q4 2022.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.